Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Autor: Lori M Laffel, Thomas Danne, Georgeanna J Klingensmith, William V Tamborlane, Steven Willi, Philip Zeitler, Dietmar Neubacher, Jan Marquard, Tatiana Bardymova, Margarita Barrientos Perez, Kathleen Bethin, Petter Bjornstad, Irina Bondar, Mimi Chen, Jin-Ho Choi, Mark A Clements, Javier Ricardo Colomar, Mark Daniels, Chaicharn Deerochanawong, Vivek S Desai, Jean-Claude G Desmangles, Robert G Dillon, Naznin M Dixit, Hongwei Du, Rachel Edelen, Diego Espinoza Peralta, María Verónica Felipe Gacioppo, Tania Maria Bulcão Lousada Ferraz, Galina Galkina, Mary Patricia Gallagher, Minu George, Edgar Gonzalez, Michael Everett Gottschalk, Giancarlo Guido, Amir Ali Hassan, Eli Hershkovitz, Lina P Huerta-Saenz, Jin Soon Hwang, Jaime Orlando Ibarra Gomez, Lydia Irizarry Gonzalez, Nina Jain, David H Jelley, Ho-Seong Kim, Tatiana Kovalenko, Lori Michelle B Laffel, Steven B Leichter, Raphael Del Roio Liberatore Jr, Jane Lynch, Farid Hussain Mahmud, Oleg Arturovich Malievskiy, Andrew Muir, Bryce A Nelson, Luis Alejandro Nevarez Ruiz, Micah L Olson, Emilia Susana Pelayo Orozco, Valentina Peterkova, Fernando Ramón Ramírez Mendoza, Konda Mohan Reddy, Henry Rodriguez, Javier Andres Saenz, Julia Samoilova, Karl-Otfried Schwab, Sejal H Shah, Naim Shehadeh, Ashley H Shoemaker, Yulia Skorodok, Aleksandr Sobolev, Silvana Ernestina Solís, Shylaja Srinivasan, Eva Tsalikian, Farida Valeeva, Carl D Vance, Pedro A Velasquez-Mieyer, Rafael Margarito Violante Ortiz, Olga Votyakova, Haiyan Wei, Ruth S Weinstock, Mark D Wheeler, Brandy Alexandra Wicklow, Steven M Willi, Kupper A Wintergerst, Risa M Wolf, Jamie Ruth Wood, Chandan Yaliwal, Hernán Yupanqui Lozno

Publikováno v: The Lancet Diabetes & Endocrinology. 11:169-181

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::638b3023bf6270d435d07dc7729ed160
https://doi.org/10.1016/s2213-8587(22)00387-4

Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes

Autor: Silva A, Arslanian, Tamara, Hannon, Philip, Zeitler, Lily C, Chao, Claudia, Boucher-Berry, Margarita, Barrientos-Pérez, Elise, Bismuth, Sergio, Dib, Jang Ik, Cho, David, Cox, Chandan, Saha

Publikováno v: The New England journal of medicine. 387(5)

The incidence of type 2 diabetes mellitus is increasing among youths. Once-weekly treatment with dulaglutide, a glucagon-like peptide-1 receptor agonist, may have efficacy with regard to glycemic control in youths with type 2 diabetes.In a double-bli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9a9346c0a8d5a7650b861922af71cd2
https://pubmed.ncbi.nlm.nih.gov/36260804

Country-Specific Prevalence and Incidence of Youth-Onset Type 2 Diabetes: A Narrative Literature Review

Autor: Margarita Kovarenko, Daniel Weghuber, Margarita Barrientos-Pérez, Mona Hafez, Jane L. Lynch, Paturi Vishnupriya Rao, Muhammad Yazid Jalaludin

Publikováno v: Annals of Nutrition and Metabolism. 76:289-296

Background: With increased awareness of type 2 diabetes (T2D) in children and adolescents, an overview of country-specific differences in epidemiology data is needed to develop a global picture of the disease development. Summary: This study examined

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a44facadbc6ef80388fc1865a7de0a7
https://doi.org/10.1159/000510499

A randomized, controlled trial of liraglutide for adolescents with obesity

Autor: Aaron S. Kelly, Marcus C, Paula M Hale, Auerbach P, Lucy D. Mastrandrea, Prabhu N, Margarita Barrientos-Pérez, Nn Trial Investigators Arslanian S, Inge Gies

Publikováno v: Yearbook of Paediatric Endocrinology.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f8b5f1d69880cafc69584e13afb2fe7
https://doi.org/10.1530/ey.17.11.12

A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)

Autor: Ólöf Thórisdóttir, Mark D. Wheeler, Margarita Barrientos-Perez, Fu Sung Lo, Nehama Zuckerman-Levin, Alison Lunsford, Bo Liang

Publikováno v: European Journal of Pediatrics

There are limited studies evaluating the safety and efficacy of treatments in young people with type 2 diabetes (T2D). This study compared the efficacy and safety of insulin detemir versus neutral protamine Hagedorn (NPH) insulin, both in combination

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90bd0fa38e200ce41bcf1b4ec1f42476
http://europepmc.org/articles/PMC6153598